Johnson & Johnson and its subsidiary Ethicon will pay nearly $117 million to settle claims that they misrepresented the risks of transvaginal surgical mesh devices, according to The Wall Street Journal.
Attorneys general in 41 states and Washington, D.C., claim J&J and Ethicon knew medical complications could arise from using the device but didn't adequately warn consumers or surgeons.
Transvaginal surgical mesh devices are used to treat pelvic organ prolapse, a condition that causes the bladder, bowel or uterus to shift, often after a hysterectomy, childbirth or menopause. Health complications linked to the devices include urinary dysfunction, loss of sexual function, constipation, pelvic pain and infection.
The settlement involves no admission of liability or misconduct from Ethicon.
Read the full article here.